{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:51:10Z","timestamp":1792799470914,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX112-11015BI"],"award-info":[{"award-number":["NHRI-EX112-11015BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX114-11401BI"],"award-info":[{"award-number":["NHRI-EX114-11401BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-007-002-MY3"],"award-info":[{"award-number":["113-2314-B-007-002-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 108-2221-E-007-104-MY5"],"award-info":[{"award-number":["NSTC 108-2221-E-007-104-MY5"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2628-E-007-022"],"award-info":[{"award-number":["113-2628-E-007-022"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2628-E-007-020"],"award-info":[{"award-number":["112-2628-E-007-020"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005057","name":"National Tsing Hua University","doi-asserted-by":"publisher","award":["113QF023E1"],"award-info":[{"award-number":["113QF023E1"]}],"id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005057","name":"National Tsing Hua University","doi-asserted-by":"publisher","award":["113QF021E1"],"award-info":[{"award-number":["113QF021E1"]}],"id":[{"id":"10.13039\/501100005057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jconrel.2025.01.066","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:51:40Z","timestamp":1738335100000},"page":"967-981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma"],"prefix":"10.1016","volume":"379","author":[{"given":"Sheng-Liang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Huang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Shin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Kuang","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Tung","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jou-Chien","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Mei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Timothy","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kak-Shan","family":"Shia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.01.066_bb0005","first-page":"41","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"Balogh","year":"2016","journal-title":"J. Hepatocel. Carcin."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0010","article-title":"New advances in the diagnosis and management of hepatocellular carcinoma","volume":"371","author":"Yang","year":"2020","journal-title":"BMJ (Clin. Res. ed.)"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2025.01.066_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072070","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"15","author":"Hagiwara","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0040","first-page":"267","article-title":"Hepatocellular carcinoma immunotherapy","volume":"73","author":"Sperandio","year":"2022"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0045","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/hep.32447","article-title":"Emerging immunotherapy for HCC: a guide for hepatologists","volume":"75","author":"Foerster","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2019.12.002","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"470","author":"Zongyi","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41423-020-00572-w","article-title":"Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells","volume":"18","author":"Ruf","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1070961","article-title":"PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0065","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2022.09.005","article-title":"Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma","volume":"164","author":"Haber","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0070","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/s12885-023-11298-z","article-title":"Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0075","article-title":"Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors","volume":"9","author":"Lung","year":"2021","journal-title":"J. ImmunoTherapy Cancer"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","article-title":"Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B","volume":"76","author":"Gao","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0105","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015433118","article-title":"A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment","volume":"118","author":"Song","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semcancer.2019.12.007","article-title":"The CXCL12-CXCR4\/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies","volume":"65","author":"Daniel","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s11658-021-00273-w","article-title":"Macrophage polarization by MSC-derived CXCL12 determines tumor growth","volume":"26","author":"Babazadeh","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2009-12-258186","article-title":"The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression","volume":"117","author":"S\u00e1nchez-Mart\u00edn","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0125","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cytogfr.2023.10.003","article-title":"An emerging paradigm of CXCL12 involvement in the metastatic cascade","volume":"75","author":"Anastasiadou","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0135","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2005-05-1937","article-title":"Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model","volume":"106","author":"Burroughs","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0140","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.2004.07.131","article-title":"Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin\u2019s lymphoma","volume":"22","author":"Devine","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0145","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1038\/s41423-021-00775-9","article-title":"Posttransplant blockade of CXCR4 improves leukemia complete remission rates and donor stem cell engraftment without aggravating GVHD","volume":"18","author":"Su","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40164-016-0050-5","article-title":"Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice","volume":"5","author":"Liu","year":"2016","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/0008-5472.CAN-10-3185","article-title":"Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer","volume":"71","author":"Rhodes","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105010","article-title":"CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent","volume":"159","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215944","article-title":"CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer","volume":"551","author":"Xie","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2023.108335","article-title":"In vivo validation of 68Ga-labeled AMD3100 conjugates for PET imaging of CXCR4","volume":"120-121","author":"Renard","year":"2023","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0175","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","article-title":"Systemic delivery of an adjuvant CXCR4\u2013CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy","volume":"16","author":"Alghamri","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081541","article-title":"Recent advances in CXCL12\/CXCR4 antagonists and nano-based drug delivery systems for cancer therapy","volume":"14","author":"Zhao","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0185","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.semcancer.2019.08.014","article-title":"Natural product-based nanoformulations for cancer therapy: opportunities and challenges","volume":"69","author":"Kashyap","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2022.08.001","article-title":"Stimuli-responsive liposomal nanoformulations in cancer therapy: pre-clinical & clinical approaches","volume":"351","author":"Ashrafizadeh","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0195","first-page":"418","article-title":"Smart nanoparticles for cancer therapy, signal transduction and targeted","volume":"8","author":"Sun","year":"2023","journal-title":"Therapy"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202204335","article-title":"Targeted Cancer immunotherapy: nanoformulation engineering and clinical translation","volume":"9","author":"Yu","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0205","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1021\/acsabm.3c00456","article-title":"CXCR4 targeting nanoplatform for transcriptional activation of latent HIV-1 infected T cells","volume":"7","author":"Vasukutty","year":"2023","journal-title":"ACS Appl. Bio Mater"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0210","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.apsb.2023.03.024","article-title":"Self-assembly of CXCR4 antagonist peptide\u2013docetaxel conjugates for breast tumor multi-organ metastasis inhibition","volume":"13","author":"Li","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0215","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.2147\/IJN.S257527","article-title":"CXCL12\/CXCR4 Axis-targeted dual-functional nano-drug delivery system against ovarian cancer","volume":"15","author":"Xue","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0220","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1016\/j.apsb.2022.12.012","article-title":"Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator","volume":"13","author":"Dong","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101106","article-title":"Fe3O4@Pt nanozymes combining with CXCR4 antagonists to synergistically treat acute myeloid leukemia","volume":"37","author":"Kong","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115328","article-title":"Recent progress in tannic acid based approaches as a natural polyphenolic biomaterial for cancer therapy: a review","volume":"166","author":"Ghasemian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0235","doi-asserted-by":"crossref","first-page":"23939","DOI":"10.1021\/acsomega.2c02727","article-title":"Tannic acid exhibits antiangiogenesis activity in nonsmall-cell lung cancer cells","volume":"7","author":"Hatami","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0240","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.26790","article-title":"Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha\/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice","volume":"59","author":"Chen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0245","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0250","doi-asserted-by":"crossref","first-page":"77110","DOI":"10.18632\/oncotarget.20363","article-title":"Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer","volume":"8","author":"Santagata","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0255","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.4049\/jimmunol.0903831","article-title":"CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors","volume":"184","author":"Rosenblum","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113561","article-title":"Pharmacological effects and mechanisms of tannic acid","volume":"154","author":"Jing","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0265","doi-asserted-by":"crossref","first-page":"28511","DOI":"10.1021\/acsami.6b10491","article-title":"Antibacterial and anti-inflammatory pH-responsive tannic acid-carboxylated agarose composite hydrogels for wound healing","volume":"8","author":"Ninan","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0270","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1039\/C5NR06335C","article-title":"CXCR4-antagonist peptide R-liposomes for combined therapy against lung metastasis","volume":"8","author":"Ierano","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0275","first-page":"147","article-title":"CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment","volume":"17","author":"Wang","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0280","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.1002\/anie.201203463","article-title":"Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion","volume":"51","author":"Li","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.colsurfb.2015.05.030","article-title":"LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells","volume":"133","author":"Wang","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2025.01.066_bb0290","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/nprot.2013.099","article-title":"Count-based differential expression analysis of RNA sequencing data using R and Bioconductor","volume":"8","author":"Anders","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0295","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0300","doi-asserted-by":"crossref","first-page":"W566","DOI":"10.1093\/nar\/gkv468","article-title":"ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap","volume":"43","author":"Metsalu","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2025.01.066_bb0305","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:44:33Z","timestamp":1777509873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":61,"alternative-id":["S0168365925000768"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.066","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}